Abstract:Background: Steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) significantly affect children's quality of life. There are frequent relapses in SSNS and progression in SRNS. IPNA guidelines suggest that monoclonal antibodies like rituximab (RTX) are promising treatments. Objective: This study aims to evaluate the long-term efficacy and safety of rituximab administration in children with SSNS, encompassing FRNS and SDNS, and SRNS over a two-year follow-up period, facilitating individualized management. Methods: We conducted an open-label, multicenter, randomized, and patient-oriented study (RICHNESS), involving children aged 3–18 with SRNS (18) and SSNS (11) undergoing 2 years continuous RTX therapy. The primary outcome was complete/partial remission (CR/PR), as defined by IPNA/KDIGO guidelines, at 6, 12, 18, and 24 months on RTX; secondary outcomes included adverse events. Key endpoints included the estimated glomerular filtration rate (eGFR), the albumin-to-creatinine ratio (ACR), CD20 levels, IgG levels, and the incidence of infections. Kidney biopsies were performed in 94% of SRNS patients. RTX was administered every 6–9 months, depending on CD20 levels, IgG levels, and the presence of infections. The eGFR and ACR were assessed every 6 months. Results: Some 31 children were selected for RTX treatment. Overall, 2 experienced severe allergic reactions, leading to their exclusion from the final analysis of 29 children. In the SSNS group, all children achieved and maintained complete remission within 2 years. Remission rates in the SRNS group ranged from 39% (RR 0.78; 95% CI: 16.4–61.4%, NNT 9) at the 6th month to 72% (RR 1.44; 95% CI: 51.5–92.9%) over the 2-year follow-up period due to continuous RTX therapy. The median duration of RTX use was 26.1 months, with a median cumulative dose of 1820 mg/m2. Adverse reactions and complications were presented by mild infusion-related reactions in 3 children (10.3%), severe allergic reactions in 2 children (6.2%), hypogammaglobulinemia in 7 children (24%), infections in 3 children (10.3%), severe destructive pneumonia in 1 child, recurrent respiratory infections in 2 children, and neutropenia in 1 child (3.44%). Conclusions: RTX was tolerated well, and proved highly effective as a steroid-sparing agent, offering potential in terms of stopping relapses and minimizing steroid-related side effects. It also demonstrated efficacy in slowing progression in SRNS, indicating potential for use in ACR reduction and renal function restoration, but requires careful use given potential severe allergic reactions and infectious complications. Further studies should focus on long-term cost-effectiveness and deferred side effects.

Rituximab treatment in pediatric‐onset multiple sclerosis

Rituximab As Maintenance Therapy Following Remission Induction in Relapsing or Refractory Systemic Lupus Erythematosus.

Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up

A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications

Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature

Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth

Single Dose of Rituximab in Children with Steroid-Dependent Minimal Change Nephrotic Syndrome

Rituximab use in paediatric nephrology practice in Türkiye: TRTX

Long－term Observation of RituXimab Therapy for Children with Frequently Relapsing Nephrotic Syndrome

Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study

B cell depletion for autoimmune diseases in paediatric patients

BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study

Efficacy of Rituximab Therapy in Children with Refractory Nephrotic Syndrome: a Prospective Observational Study in Shanghai

Protocol for an Open-Label, Single-Arm, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Rituximab in the First Episode of Paediatric Idiopathic Nephrotic Syndrome

Safety and efficacy of Rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece

Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease

Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?

Analysis of efficacy of rituximab in treating primary focal segmental glomerulosclerosis in children

Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder

Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study

The indications and safety of rituximab for the treatment of pediatric autoimmune diseases: a single-center retrospective study